This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Congenital Nephrotic Syndrome, Crescentic Glomerulonephritis미만성 반월형 사구체신염 선천성 신증후군 (미만성 반월형 사구체신염 선천성신증후군)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: N04.7 (congenital nephrotic syndrome with diffuse crescentic glomerulonephritis / extracapillary glomerulonephritis) | Special Copayment Reduction: V263 (rare disease)
B. SynonymsCongenital nephrotic syndrome with diffuse crescentic glomerulonephritis | congenital nephrotic syndrome with extracapillary glomerulonephritis
C. Adult onsetLikelihood of first onset in adulthood: very low — crescentic congenital nephrotic syndrome presents abruptly within a few weeks to 1 year after birth, and there are virtually no cases that remain asymptomatic until adulthood. Given the clinical course of RPGN, early presentation and rapid diagnosis · treatment are essential.
1. HistoryCrescentic glomerulonephritis described by Volhard/Fahr in 1914; pediatric · infantile crescentic CNS rarely reported; classification system of three etiologies established: ANCA, anti-GBM, immune complex
2. CausesAnti-GBM antibody–mediated (Goodpasture syndrome–like), ANCA-associated small vessel vasculitis, immune complex–mediated (lupus, IgA nephropathy, progressive MPGN); congenital onset is mainly associated with the immune complex type or complement abnormalities
3. GeneticsHereditary causes rare; ANCA risk genes such as HLA-DRB1*15:01; HLA-DR2 associated with anti-GBM antibody disease; evaluation for genetic causes needed in congenital onset
4. General epidemiologyCrescentic glomerulonephritis overall about 7 per 1 million; congenital · infantile onset extremely rare; a few dozen cases of neonatal · infantile crescentic GN in the literature
5. PathophysiologyProliferating cells in Bowman's space (parietal epithelial cells, infiltrating monocytes) form crescents → loss of glomerular function; immune complex– or ANCA-mediated glomerular injury precedes
6. SymptomsRapid decline in renal function (rapidly progressive glomerulonephritis, RPGN); hematuria, proteinuria, hypertension, oliguria/anuria; hemoptysis with pulmonary involvement (anti-GBM or ANCA)
7. SignsCrescentic findings on light microscopy; serum ANCA (MPO or PR3), anti-GBM antibodies; rapid creatinine rise; linear (anti-GBM) or granular (immune complex) deposits on immunofluorescence
8. ScreeningImmediate ANCA, anti-GBM antibody, and complement testing when clinically suspected; monitoring of mothers with high-risk autoimmune diseases
9. DiagnosisImmediate renal biopsy (confirmation of crescent formation), ANCA, anti-GBM, complement, autoantibody panel; rapid diagnosis is decisive for the timing of treatment initiation
10. TreatmentEmergency high-dose pulse steroids + cyclophosphamide; plasma exchange (if anti-GBM antibody positive); rituximab (ANCA-associated); eculizumab (with complement abnormalities)
11. PrognosisWithout prompt treatment, progression to ESRD within weeks to months; poor prognosis with crescent formation > 50%; treatment toxicity must be considered in infants
12. PreventionMonitoring of maternal autoantibodies; early recognition of infantile crescentic GN; genetic counseling (with complement abnormalities)
13. References10 key references (with PMID or DOI)

1. History

Diffuse crescentic glomerulonephritis (CrGN) is a histologic type in which crescent-shaped cellular proliferative lesions form within Bowman's space in 50% or more of glomeruli on renal biopsy, presenting clinically as rapidly progressive glomerulonephritis (RPGN). In 1914, the German pathologists Volhard and Fahr first systematically described this histologic finding in glomerular diseases causing acute renal failure.

In the mid-20th century, crescentic glomerulonephritis was shown to be caused by anti–glomerular basement membrane (anti-GBM) antibodies and was recognized as the renal form of Goodpasture syndrome (anti-GBM antibodies + pulmonary hemorrhage). In the 1980s, the same crescentic glomerulonephritis was confirmed to occur in ANCA (antineutrophil cytoplasmic antibody)–associated small vessel vasculitis, and in the 1990s Jennette and Falk established a system classifying crescentic glomerulonephritis into ① anti-GBM antibody–mediated (Type I), ② the form without immune deposits ('pauci-immune', mainly ANCA-associated, Type II), and ③ immune complex–mediated (Type III).

Crescentic glomerulonephritis with congenital or infantile onset is extremely rare, and only a few dozen cases have been reported in the literature. In this age group, immune complex-mediated forms (neonatal lupus, progression of complement abnormalities, complications of congenital infection) are relatively more relevant, while anti-GBM or ANCA-associated forms are very rare in infants. Case reports of pediatric crescentic glomerulonephritis exist in Korea as well, but congenital onset is extremely rare.

2. Causes

The causes of crescentic congenital nephrotic syndrome are classified into three types according to pathogenic mechanism.

Immune complex-mediated type (Type III): the form most relevant to congenital and infantile onset. Reported causes include neonatal lupus (transfer of maternal anti-dsDNA antibodies), advanced congenital infection (CMV, syphilis), transition of MPGN or C3 glomerulopathy to a crescentic form, IgA nephropathy (infantile form of Henoch-Schönlein purpura nephritis), and mixed cryoglobulinemia. The process proceeds as deposition of immune complexes within the GBM or subepithelially → complement activation → glomerular rupture → fibrin exudation → crescent formation in Bowman's space.

Anti-GBM antibody-mediated type (Type I): a major cause in adults and adolescents, but extremely rare in infants. Reported cases of congenital onset are absent or very rare. Anti-GBM antibodies bind to the Goodpasture antigen (NC1 domain of the α3 chain), activating complement and damaging the glomeruli.

ANCA-associated type (Type II, pauci-immune): renal involvement of small-vessel vasculitis due to MPO-ANCA (microscopic polyangiitis) or PR3-ANCA (Wegener granulomatosis, GPA). Extremely rare in infants and rarely reported in children. Placental transfer of maternal ANCA can cause transient ANCA-related symptoms in newborns.

3. Genetics

Most crescentic glomerulonephritis has no single-gene cause; it is an acquired or quasi-acquired (maternal antibody transfer) disease caused by autoimmune or immune complex-mediated mechanisms.

HLA association: an association between anti-GBM antibody disease and the HLA-DR2 (DRB1*15:01) genotype has been reported, and associations of ANCA-associated vasculitis with the HLA-DPB1*04:01 (MPO-ANCA) and HLA-DPA1*03:01 (PR3-ANCA) genotypes are known. However, the role of these genetic risk factors in pediatric and infantile onset is not as clear as in adults.

Association with complement abnormalities: in patients with complement pathway gene variants (CFH, CFI, C3, etc.), underlying C3 glomerulopathy or MPGN has rarely been reported to progress to a crescentic form. In such cases, the inherited complement abnormality is the underlying cause of crescentic glomerulonephritis.

Genetic testing strategy: when a complement gene abnormality is suspected in congenital onset (low C3, normal C4), a complement gene panel is performed. When ANCA and anti-GBM antibodies are negative and there is no complement abnormality, the cause of the immune complex-mediated form is investigated in the direction of infection and autoimmunity (lupus).

4. General epidemiology

In adults, crescentic glomerulonephritis accounts for about 2–4% of glomerular diseases, with an estimated incidence of about 7 per million. Crescentic glomerulonephritis in children is also rare, with a lower incidence than in adults. Only a few dozen cases of crescentic glomerulonephritis with congenital or infantile (under 1 year) onset have been reported in the literature worldwide, making estimation of its incidence practically impossible.

In pediatric crescentic glomerulonephritis, the main causes are the ANCA-associated type, HSP (IgA vasculitis) nephritis, and lupus nephritis (Class IV-V). In infantile onset, the immune complex-mediated type is relatively more common, which is associated with infection or maternal antibody transfer. Cases of pediatric crescentic glomerulonephritis have been reported in Korea, but the number of registered congenital (N04.7) patients is extremely small. Because of rapid decline in renal function and high mortality, prompt diagnosis and treatment of crescentic glomerulonephritis are essential, and delay leads to irreversible kidney damage.

5. Pathophysiology

In crescentic glomerulonephritis, crescents form when fibrin, plasma proteins, monocytes/macrophages, and parietal epithelial cells (PEC) leak into Bowman's space through ruptures in the glomerular basement membrane and proliferate.

Process of crescent formation: ① immune-mediated (anti-GBM, ANCA, immune complex) glomerular injury → ② GBM rupture → ③ leakage of plasma proteins and fibrin into Bowman's space → ④ PEC activation and proliferation, recruitment of infiltrating monocytes/macrophages → ⑤ formation of cellular crescents → ⑥ fibrosis (fibrotic crescent, as tissue damage progresses) → ⑦ complete loss of the glomerulus with tubular atrophy and interstitial fibrosis.

ANCA-associated mechanism: PR3-ANCA or MPO-ANCA activates neutrophils in microvasculitic lesions, destroying small-vessel walls and damaging the glomerular capillary endothelium. Because immune deposits are absent or minimal, it is classified as 'pauci-immune' CrGN. Anti-GBM antibody-mediated mechanism: IgG anti-GBM antibodies bind to the NC1 domain of the α3(IV) chain of the GBM → activation of the classical complement pathway → GBM rupture → crescent formation. Immune complex-mediated mechanism: subendothelial and mesangial immune complexes → complement and neutrophil activation → GBM injury → crescent formation. Glomeruli with crescents completely lose filtration function, so when the proportion of crescents is > 50%, the risk of irreversible renal failure is high.

6. Symptoms

Crescentic congenital nephrotic syndrome is characterized by rapid decline in renal function (rapidly progressive glomerulonephritis, RPGN), and its clinical course is the fastest and most severe compared with other congenital nephrotic syndrome subtypes.

Renal symptoms: rapid decline in renal function over days to weeks (abrupt rise in serum creatinine, GFR reduction of 50% or more) is the key finding of RPGN. Gross or microscopic hematuria (including RBC casts) and proteinuria (possibly in the nephrotic range) accompany it. Oliguria or anuria may occur. Hypertension is common, and severe hypertension may be accompanied by hypertensive encephalopathy. Generalized edema occurs due to fluid retention from renal failure.

Systemic symptoms: pulmonary involvement (pulmonary hemorrhage, hemoptysis) may accompany anti-GBM or ANCA-associated types but is very rare in infants. In lupus-associated crescentic forms (neonatal lupus or maternal antibody transfer), lupus findings such as facial erythema, cytopenia, and liver function abnormalities may accompany it. In the immune complex-mediated type, low complement (C3, C4) is present. In infants, it often presents with nonspecific symptoms such as feeding refusal, lethargy, pallor, abdominal distension, and failure to thrive, making early recognition difficult.

7. Signs

Physical examination: elevated blood pressure (hypertension), edema, pallor (anemia). Oliguria or anuria. With pulmonary involvement, decreased breath sounds or crackles (pulmonary hemorrhage). With lupus association, facial erythema and rash.

Laboratory findings: urine: gross or microscopic hematuria (RBC casts), proteinuria (2–4+). Abrupt rise in serum creatinine (days to weeks). Elevated BUN. CBC: anemia (hemolytic or renal anemia), thrombocytopenia (with lupus or aHUS). ANCA (MPO, PR3): positive in the ANCA-associated type. Anti-GBM antibody: positive in the anti-GBM type. ANA, anti-dsDNA: to exclude lupus association. C3, C4: low in the immune complex-mediated type and lupus. C3NeF: with complement abnormality association.

Kidney biopsy findings: light microscopy: cellular or fibrous crescents in Bowman's space in > 50% of glomeruli. Sites of GBM rupture identified. Crescent cell composition (PEC, monocytes/macrophages, fibrin) confirmed with PAS, Masson, and Jones silver stains. Immunofluorescence: Type I (anti-GBM) - linear deposition of IgG along the GBM. Type II (ANCA) - no deposits (pauci-immune). Type III (immune complex) - granular deposits of IgG, IgM, C3. Electron microscopy: deposit patterns according to type.

8. Screening

Because rapid diagnosis is decisive for the prognosis of crescentic glomerulonephritis, emergency testing is required as soon as it is clinically suspected.

Immediate testing based on clinical suspicion: when an infant has rapid decline in renal function over days to weeks (abrupt rise in creatinine) with hematuria and oliguria/anuria, ANCA (MPO, PR3), anti-GBM antibody, C3, C4, ANA, anti-dsDNA, and TORCH panel tests are performed immediately. If RBC casts are found on urinalysis, crescentic glomerulonephritis is included as an emergency differential diagnosis.

Monitoring of high-risk mothers: in newborns of mothers with ANCA-positive small-vessel vasculitis or SLE, autoantibody levels are measured early. Because maternal antibodies disappear within 3–6 months after birth, renal function and urinalysis are monitored regularly during this period. In newborns from families with complement abnormalities (CFH variants), complement levels are monitored and the possibility of progression to a crescentic form is kept in mind.

9. Diagnosis

Emergency kidney biopsy is central to the diagnosis of crescentic glomerulonephritis and must be performed promptly without delaying treatment.

Clinical criteria: the combination of RPGN (GFR reduction of 50% or more within weeks) + hematuria + proteinuria + hypertension strongly suggests crescentic GN.

Emergency kidney biopsy: kidney biopsy is performed as soon as crescentic GN is suspected. Crescentic GN is confirmed when crescents are seen in > 50% of glomeruli on light microscopy. The type is classified by the immunofluorescence deposition pattern: linear (anti-GBM), negative (pauci-immune), or granular (immune complex). Electron microscopy confirms the deposition pattern of each type.

Autoantibody and complement tests: ANCA (MPO, PR3), anti-GBM antibody, ANA, anti-dsDNA, C3, C4, C3NeF, anti-CFH antibody. Complement gene panel if needed. Blood for these tests is drawn at the same time as the biopsy, and the biopsy proceeds without waiting for results. TORCH, ANCA, serum cultures, CRP, and PCT to exclude infectious causes.

Imaging: renal ultrasound (assessment of kidney size and echogenicity), chest X-ray (to check pulmonary involvement), brain MRI (with hypertensive encephalopathy).

10. Treatment

Because prompt treatment is decisive for the prognosis of crescentic glomerulonephritis, it is recommended that treatment start as soon as it is suspected, without waiting for biopsy results and autoantibody tests.

Emergency pulse steroid therapy: intravenous pulse methylprednisolone (30 mg/kg/day, maximum 1 g, for 3 consecutive days) immediately suppresses acute glomerular inflammation. This is followed by a switch to oral prednisolone (2 mg/kg/day), tapered over several months.

Cyclophosphamide: used in combination with steroids in the ANCA-associated or immune complex-mediated type. The pediatric dose is 2–3 mg/kg/day orally or IV pulse (500–1000 mg/m² monthly). Adequate fluids and mesna are given to prevent bladder toxicity (hemorrhagic cystitis).

Plasmapheresis: in the anti-GBM antibody-mediated type, emergency plasma exchange (daily or every other day, for 1–2 weeks) is performed to remove circulating anti-GBM antibodies. It is also considered in the ANCA-associated type with severe pulmonary hemorrhage or dialysis-dependent renal failure. Plasma exchange in infants is technically difficult but is performed at some centers.

Rituximab: used in the ANCA-associated type as an alternative to cyclophosphamide or at relapse. Clinical evidence from adults is extrapolated to children.

Eculizumab: considered as complement inhibition therapy in crescentic GN associated with complement abnormalities (CFH deficiency, etc.). Prior meningococcal vaccination is mandatory.

Dialysis and kidney transplantation: when fluid overload, electrolyte abnormalities, and uremia due to acute renal failure cannot be controlled, dialysis (hemodialysis or peritoneal dialysis) is started immediately. Kidney transplantation upon progression to ESRD. Post-transplant recurrence of crescentic GN varies by type (anti-GBM type: transplantation possible after the underlying antibodies disappear, recurrence rare; ANCA type: relatively low recurrence rate; immune complex type: varies with the cause).

11. Prognosis

Crescentic glomerulonephritis is a disease with poor prognosis that progresses to ESRD within weeks to months without treatment. Prognosis varies greatly with the proportion of crescents, timing of treatment initiation, type, and treatment response.

Proportion of crescents and prognosis: with crescents > 50%, the risk of irreversible renal failure is very high, and with > 75%, recovery of renal function is impossible in most cases. The lower the serum creatinine level at the start of treatment, the greater the likelihood of renal recovery. The more fibrous crescents (advanced stage of tissue damage), the poorer the prognosis.

Prognosis by type: anti-GBM antibody-mediated type: renal function can be preserved in about 50% with early plasma exchange + immunosuppressive therapy. Pulmonary hemorrhage is the main cause of death. ANCA-associated type: about 50–70% of initially dialysis-dependent patients can come off dialysis after treatment. Risk of relapse. Immune complex-mediated type: recovery is possible with removal of the cause and immunosuppression, but prognosis differs greatly depending on the cause.

Special considerations for infantile onset: when using high-dose immunosuppressants (steroids, cyclophosphamide) in infants, the dose and duration are minimized in consideration of infection risk, effects on growth, and gonadal toxicity (cyclophosphamide). Evidence for pediatric use of rituximab is more limited than in adults. Assessment of and preparation for post-transplant recurrence risk are required.

12. Prevention

Crescentic glomerulonephritis is an emergency, and early recognition and prompt treatment are more important than prevention.

Maternal monitoring: in mothers with ANCA-positive small-vessel vasculitis, SLE, or anti-GBM antibody positivity, newborn monitoring is performed with placental transfer of maternal autoantibodies in mind. In mothers with SLE, control of anti-dsDNA antibody levels minimizes neonatal lupus and its renal involvement.

Genetic counseling for families with complement abnormalities: newborns from families with complement gene variants (CFH, etc.) have complement levels and urine protein/hematuria monitored regularly so that progression to a crescentic form is detected early and treatment is started immediately. Preparations are made for early use of eculizumab and meningococcal vaccination.

Early recognition and immediate treatment: when an infant has rapid decline in renal function (days to weeks), hematuria, hypertension, and oliguria, immediately refer to a pediatric nephrology team and perform an emergency biopsy. It must always be recognized that time-to-treatment is the most important factor for renal recovery.


13. References

  1. Jennette JC, Olson JL, Silva FG, et al. Heptinstall's Pathology of the Kidney, 7th ed. Wolters Kluwer; 2015. (Reference for histologic classification criteria of crescentic glomerulonephritis).
  2. Alchi B, Jayne D. Membranoproliferative glomerulonephritis. Pediatr Nephrol. 2010;25(8):1409-1418. DOI: 10.1007/s00467-009-1208-x. PMID: 19479290.
  3. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36-44. DOI: 10.1056/NEJMoa020286. PMID: 12840090.
  4. Couser WG. Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis. 1988;11(6):449-464. DOI: 10.1016/S0272-6386(88)80079-7. PMID: 3287861.
  5. Trautmann A, Vivarelli M, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020;35(8):1529-1561. DOI: 10.1007/s00467-020-04519-1. PMID: 32382828.
  6. Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2009;60(7):2156-2168. DOI: 10.1002/art.24637. PMID: 19565480.
  7. Kaplan BS, Meyers KE, Schulman SL. The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol. 1998;9(6):1126-1133. PMID: 9621302.
  8. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis — a new look at an old entity. N Engl J Med. 2012;366(12):1119-1131. DOI: 10.1056/NEJMra1108178. PMID: 22435371.
  9. Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: KDIGO Controversies Conference. Kidney Int. 2017;91(3):539-551. DOI: 10.1016/j.kint.2016.10.005. PMID: 28094080.
  10. Kim JH, Han KH, Lee JM, et al. Genetic and clinical characteristics of childhood-onset nephrotic syndrome in Korea. J Korean Med Sci. 2019;34(6):e55. DOI: 10.3346/jkms.2019.34.e55. PMID: 30799572.